Home World News Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with... World News Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions By Ogkologos - June 23, 2026 254 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the WU-KONG28 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma April 29, 2021 Triplet Therapy with ADT, Docetaxel and Abiraterone Plus Prednisone Improves Survival... May 2, 2022 Utility of Genomic Profiling of cfDNA to Inform Clinical Care for... September 28, 2022 Man Who Lost Wife to Breast Cancer Wants to Donate Her... June 5, 2021 Load more HOT NEWS 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... Quantitative Summary of QoL Data Confirms Immune Checkpoint Inhibitor Therapy Is... New chemotherapy-free treatment for bowel cancer made available in Scotland Why the Fear of Cancer Recurrence Is Often Misunderstood and How...